Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study is being done to see if we can improve the response of Interleukin-2 by adding
Zoledronic acid. The effectiveness of the combination of drugs in kidney cancer is unknown
and will be investigated in this study. In particular, this study will evaluate the effect of
this combination on kidney cancer and will also examine the safety and side effects of IL-2
with Zoledronic acid.